Myriad Genetics, Inc. (NASDAQ:MYGN) Insider Nicole Lambert Sells 4,354 Shares of Stock

Myriad Genetics, Inc. (NASDAQ:MYGN) insider Nicole Lambert sold 4,354 shares of Myriad Genetics stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $19.73, for a total transaction of $85,904.42. Following the sale, the insider now owns 59,150 shares of the company’s stock, valued at $1,167,029.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of MYGN opened at $19.54 on Friday. The firm has a market cap of $1.48 billion, a P/E ratio of -54.28, a P/E/G ratio of 11.31 and a beta of 0.99. The stock has a 50 day simple moving average of $27.00 and a two-hundred day simple moving average of $28.22. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.86 and a quick ratio of 2.61. Myriad Genetics, Inc. has a 1 year low of $19.08 and a 1 year high of $48.40.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.22 by $0.01. The firm had revenue of $195.10 million for the quarter, compared to the consensus estimate of $209.61 million. Myriad Genetics had a negative net margin of 3.22% and a positive return on equity of 5.42%. The business’s revenue was down 10.0% compared to the same quarter last year. During the same period last year, the firm posted $0.38 earnings per share. On average, equities analysts anticipate that Myriad Genetics, Inc. will post 0.15 earnings per share for the current year.

MYGN has been the subject of a number of research reports. Zacks Investment Research cut shares of Myriad Genetics from a “hold” rating to a “sell” rating and set a $21.00 price target for the company. in a research note on Thursday. Barclays lowered their price objective on shares of Myriad Genetics from $22.00 to $18.00 and set an “underweight” rating on the stock in a research report on Tuesday, November 5th. Needham & Company LLC started coverage on shares of Myriad Genetics in a report on Friday, January 3rd. They set a “strong-buy” rating and a $36.00 price objective for the company. Leerink Swann cut their target price on shares of Myriad Genetics from $37.00 to $28.00 and set a “market perform” rating for the company in a research report on Tuesday, November 5th. Finally, Piper Jaffray Companies reduced their target price on Myriad Genetics from $40.00 to $22.00 in a research note on Tuesday, November 5th. Four research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a strong buy rating to the company’s stock. Myriad Genetics currently has a consensus rating of “Hold” and an average price target of $25.16.

Institutional investors have recently made changes to their positions in the company. Advisory Services Network LLC raised its position in Myriad Genetics by 104.3% in the 4th quarter. Advisory Services Network LLC now owns 1,083 shares of the company’s stock worth $29,000 after purchasing an additional 553 shares during the period. Evoke Wealth LLC purchased a new position in shares of Myriad Genetics in the third quarter worth about $44,000. Meeder Asset Management Inc. purchased a new position in shares of Myriad Genetics in the third quarter worth about $52,000. First Bank & Trust increased its holdings in shares of Myriad Genetics by 583.7% in the fourth quarter. First Bank & Trust now owns 2,181 shares of the company’s stock worth $59,000 after buying an additional 1,862 shares during the period. Finally, Exchange Traded Concepts LLC bought a new stake in shares of Myriad Genetics in the 4th quarter valued at about $85,000.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Recommended Story: Why do analysts give a neutral rating?

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.